Neurizon Therapeutics Limited has released a press release.
Appendix 4E & Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Chief Executive Officer Appointment
- Additional Phase 1 data suggest MPL may inhibit MND
- Cohort 3 Pharmacokinetics in MND Patients Completed
- Epichem enters voluntary liquidation
- MND Trial Successfully Completes 3rd Patient Cohort
Later from Neurizon Therapeutics
- Canine Oncology Data Supports Progression to Registration
- Final MND Patient in Cohort 4 Successfully Completes Dosing
- Options Offer to Existing Listed Option Holders
- Appendix 4C and Quarterly Update
- Prospectus & Target Market Determination
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics